

Todd M Bauer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3869665/publications.pdf>

Version: 2024-02-01

62
papers

7,398
citations

117453

34
h-index

143772

57
g-index

63
all docs

63
docs citations

63
times ranked

9863
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100262.	0.6	7
2	Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes. <i>JCO Precision Oncology</i> , 2022, 6, e2100456.	1.5	11
3	Podcast on the Management of Adverse Events Associated with Lorlatinib. <i>Advances in Therapy</i> , 2022, 39, 1447.	1.3	1
4	Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i> -Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3593-3602.	0.8	43
5	Immunologic and tumor responses of pegilodecafin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). <i>Investigational New Drugs</i> , 2021, 39, 182-192.	1.2	8
6	Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma. <i>Investigational New Drugs</i> , 2021, 39, 1081-1088.	1.2	10
7	Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies. <i>Cancer Treatment Reviews</i> , 2021, 95, 102173.	3.4	14
8	Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. <i>Investigational New Drugs</i> , 2020, 38, 812-820.	1.2	33
9	Population pharmacokinetics of vactosertib, a new TGF- β 2 receptor type 1 inhibitor, in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 173-183.	1.1	22
10	First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2018-2029.	13.9	592
11	Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers. <i>New England Journal of Medicine</i> , 2020, 383, 825-835.	13.9	454
12	Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 461-468.e3.	0.9	60
13	Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 469-476.e4.	0.9	16
14	Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated <i>ALK</i> -Positive Non-Small-Cell Lung Cancer. <i>Targeted Oncology</i> , 2020, 15, 55-65.	1.7	86
15	Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response. <i>Clinical Cancer Research</i> , 2020, 26, 2176-2187.	3.2	54
16	A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. , 2020, 8, e000530.		54
17	Phase 1 study of capmatinib in <i>MET</i> -positive solid tumor patients: Dose escalation and expansion of selected cohorts. <i>Cancer Science</i> , 2020, 111, 536-547.	1.7	44
18	Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. <i>Investigational New Drugs</i> , 2019, 37, 271-281.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 87-97.	1.2	59
20	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 121-133.	1.1	4
21	Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 831-840.	0.6	31
22	Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1691-1701.	5.1	233
23	Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1828-1838.	0.5	50
24	Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1544-1555.	5.1	86
25	Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	1.5	14
26	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5202-5211.	3.2	26
27	Clinical Management of Adverse Events Associated with Lorlatinib. <i>Oncologist</i> , 2019, 24, 1103-1110.	1.9	101
28	Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1464-1473.	1.1	9
29	<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1370-1379.	0.8	282
30	Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. <i>Clinical Cancer Research</i> , 2019, 25, 1727-1736.	3.2	39
31	Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. <i>Oncotarget</i> , 2019, 10, 6526-6535.	0.8	15
32	A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3253-3262.	3.2	71
33	Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. <i>ESMO Open</i> , 2018, 3, e000291.	2.0	37
34	Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora kinase inhibitor in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2018, 36, 248-258.	1.2	16
35	Effect of alisertib, an investigational aurora kinase inhibitor on the QTc interval in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2018, 36, 240-247.	1.2	5
36	First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 3298-3306.	0.8	88

#	ARTICLE	IF	CITATIONS
37	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). <i>Journal of Clinical Oncology</i> , 2018, 36, 3223-3230.	0.8	267
38	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 1654-1667.	5.1	587
39	A Phase Ib study of ruxolitinib + gemcitabine & plusmn nab-paclitaxel in patients with advanced solid tumors. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2399-2407.	1.0	11
40	Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. , 2018, 6, 109.		151
41	Signature program: a platform of basket trials. <i>Oncotarget</i> , 2018, 9, 21383-21395.	0.8	36
42	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017, 7, 400-409.	7.7	647
43	Phase <sc>II</sc> study of bendamustine, bortezomib and dexamethasone (<sc>BBD</sc>) in the firstâ€line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. <i>British Journal of Haematology</i> , 2017, 177, 254-262.	1.2	6
44	Phase 1 doseâ€escalation study of mirvetuximab soravtansine (<sc>IMGN853</sc>), a folate receptor 1â€targeting antibodyâ€drug conjugate, in patients with solid tumors. <i>Cancer</i> , 2017, 123, 3080-3087.	2.0	94
45	Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. <i>Lancet Oncology</i> , The, 2017, 18, 42-51.	5.1	412
46	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1590-1599.	5.1	535
47	Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 2423-2432.	3.2	50
48	Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study. <i>Experimental Hematology and Oncology</i> , 2017, 6, 27.	2.0	10
49	Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alphaâ€Targeting Antibodyâ€Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1112-1118.	0.8	158
50	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1764-1771.	0.8	149
51	Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 3562-3569.	0.8	175
52	A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors. <i>Cancer Investigation</i> , 2016, 34, 265-270.	0.6	34
53	Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1670-1674.	0.5	197
54	Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. , 2015, 3, .		66

#	ARTICLE	IF	CITATIONS
55	Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. <i>Cancer Discovery</i> , 2015, 5, 850-859.	7.7	632
56	A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 463-471.	1.2	75
57	Targeting PI3 kinase in cancer. , 2015, 146, 53-60.		129
58	Abstract CT139: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors. <i>Cancer Research</i> , 2015, 75, CT139-CT139.	0.4	6
59	Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours. <i>European Journal of Cancer</i> , 2014, 50, 2897-2904.	1.3	40
60	Carbohydrate antigen 19â€9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabineâ€containing chemotherapy. <i>Cancer</i> , 2013, 119, 285-292.	2.0	103
61	Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1269-1279.	2.0	134
62	A 17 Year-Old Man with an Exon 11 Mutation of CD-117 Causing a Gastrointestinal Stromal Tumor. <i>Cancer Investigation</i> , 2008, 26, 182-184.	0.6	6